Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
9 "Myung Chul Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
The Relationship between Expression of the Sodium/iodide Symporter Gene and the Status of Hormonal Receptors in Human Breast Cancer Tissue
Hyun Jung Oh, June-Key Chung, Joo Hyun Kang, Won Jun Kang, Dong Young Noh, In Ae Park, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
Cancer Res Treat. 2005;37(4):247-250.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.247
AbstractAbstract PDFPubReaderePub
Purpose

It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in human breast cancer tissues.

Materials and Methods

Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry.

Results

The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05).

Conclusion

The NIS gene is expressed in approximately one-third of the human breast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.

Citations

Citations to this article as recorded by  
  • Benign thyroid disease and the risk of breast cancer: An updated systematic review and meta-analysis
    Mingyue Han, Yao Wang, Yuanhui Jin, Xue Zhao, Haiying Cui, Guixia Wang, Xiaokun Gang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions
    Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen
    Cancers.2022; 14(20): 5117.     CrossRef
  • Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
    Marwa M. Mahmoud, Eman F. Sanad, Reham A.A. Elshimy, Nadia M. Hamdy
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The correlation between breast cancer and urinary iodine excretion levels
    Fatma Umit Malya, Huseyin Kadioglu, Mustafa Hasbahceci, Kemal Dolay, Mehmet Guzel, Yeliz Emine Ersoy
    Journal of International Medical Research.2018; 46(2): 687.     CrossRef
  • Different expression of sodium–iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR)
    X.-Z. Shi, L. Xue, X. Jin, P. Xu, S. Jia, H.-M. Shen
    Journal of Endocrinological Investigation.2017; 40(1): 41.     CrossRef
  • Is there an association between thyroid function abnormalities and breast cancer?
    Anna Angelousi, Evanthia Diamanti-Kandarakis, Evangelia Zapanti, Afroditi Nonni, Eftuxios Ktenas, Aimilia Mantzou, Konstantinos Kontzoglou, Grigorios Kouraklis
    Archives of Endocrinology and Metabolism.2017; 61(1): 54.     CrossRef
  • Iodide transport and breast cancer
    Vikki L Poole, Christopher J McCabe
    Journal of Endocrinology.2015; 227(1): R1.     CrossRef
  • The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer
    Chang Min Park, Young Don Lee, Eun Mee Oh, Kwan-Il Kim, Heung Kyu Park, Kwang-Pil Ko, Yoo Seung Chung
    Annals of Surgical Treatment and Research.2014; 86(4): 169.     CrossRef
  • Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
    Salvatore Micali, Stefania Bulotta, Cinzia Puppin, Angelo Territo, Michele Navarra, Giampaolo Bianchi, Giuseppe Damante, Sebastiano Filetti, Diego Russo
    BMC Cancer.2014;[Epub]     CrossRef
  • TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
    Paweł Szychta, Wojciech Szychta, Adam Gesing, Andrzej Lewiński, Małgorzata Karbownik-Lewińska
    Thyroid Research.2013;[Epub]     CrossRef
  • Quantitative Immunohistochemical Analysis Reveals Association between Sodium Iodide Symporter and Estrogen Receptor Expression in Breast Cancer
    Sushmita Chatterjee, Renu Malhotra, Frency Varghese, Amirali B. Bukhari, Asawari Patil, Ashwini Budrukkar, Vani Parmar, Sudeep Gupta, Abhijit De, Pranela Rameshwar
    PLoS ONE.2013; 8(1): e54055.     CrossRef
  • Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer
    Sasha J Beyer, Xiaoli Zhang, Rafael E Jimenez, Mei-Ling T Lee, Andrea L Richardson, Kun Huang, Sissy M Jhiang
    BMC Research Notes.2011;[Epub]     CrossRef
  • Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?
    S. J. Beyer, R. E. Jimenez, C. L. Shapiro, J. Y. Cho, S. M. Jhiang
    Breast Cancer Research and Treatment.2009; 115(1): 205.     CrossRef
  • 11,461 View
  • 64 Download
  • 13 Crossref
Close layer
Usefulness of Additional Delayed Regional F-18 Fluorodeoxy-glucose Positron Emission Tomography in the Lymph Node Staging of Non-Small Cell Lung Cancer Patients
Young So, June-Key Chung, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
Cancer Res Treat. 2005;37(2):114-121.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.114
AbstractAbstract PDFPubReaderePub
Purpose

In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients.

Materials and Methods

Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes.

Results

Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole bodyscan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71±1.08, 5.18±1.60, and 42.59±33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45±0.73, 3.00±0.89, and 22.71±20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes.

Conclusion

Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.

Citations

Citations to this article as recorded by  
  • KSNM60 in Clinical Nuclear Oncology
    Seung Hwan Moon, Young Seok Cho, Joon Young Choi
    Nuclear Medicine and Molecular Imaging.2021; 55(5): 210.     CrossRef
  • 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and backgro
    Stephen P Povoski, Douglas A Murrey, Sabrina M Smith, Edward W Martin, Nathan C Hall
    BMC Cancer.2014;[Epub]     CrossRef
  • Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy
    Hyun-Cheol Kang, Hong-Gyun Wu, Tosol Yu, Hak Jae Kim, Jin Chul Paeng
    Radiation Oncology Journal.2013; 31(3): 111.     CrossRef
  • Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting
    Thomas C. Kwee, Sandip Basu, Drew A. Torigian, Babak Saboury, Abass Alavi
    European Journal of Nuclear Medicine and Molecular Imaging.2011; 38(7): 1353.     CrossRef
  • Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement
    Minyoung Oh, Ji Young Kim, Kwang-Ho Shin, Seol Hoon Park, Jin-Sook Ryu, Jae Seung Kim, Hye-Jin Kim, Dong-Wha Kang, Dae Hyuk Moon
    Nuclear Medicine and Molecular Imaging.2010; 44(4): 261.     CrossRef
  • 10,155 View
  • 48 Download
  • 5 Crossref
Close layer
Clinical Value of Whole Body F-18 FDG PET in The Management of Recurrent Colorectal Malignancy
Seok Byung Lim, Hyo Seong Choi, Sung Bum Kang, Seung Chul Heo, Young Jin Park, Seung Yong Jeong, Kyu Joo Park, Han Kwang Yang, Kyung Hoon Hwang, Jae Min Jeong, Dong Soo Lee, June Key Chung, Myung Chul Lee, Keon Wook Kang, Jae Gahb Park
Cancer Res Treat. 2003;35(4):349-354.   Published online August 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.4.349
AbstractAbstract PDF
PURPOSE
The aim of this study was to evaluate the clinical value of whole body 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the patient with a recurrence of a previously treated colorectal malignancy.
MATERIALS AND METHODS
Fifty-eight cases were scanned using PET at the PET Center of Seoul National University Hospital between May 1995 and Aug 2002. All the patients had had a previous operation for a colorectal malignancy. The PET scans were performed for the following reasons: - investigation of a recurrence (n=12), investigation of the operability (n=38) and clinical follow up (n=8). In these 58 cases, 47 of the CT scans and 55 of the CEA (Carcinoembryonic antigen) were checked prior to the FDG- PET. The accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the PET scans were calculated, and compared with those of conventional CT scan and CEA, which were also compared with the previous reported data. Eight cases, whose managements were influenced by the PET findings, were analyzed.
RESULTS
Recurrences, or metastases, of colorectal cancer developed in 51 cases, with 49 of these being detected by the PET. The accuracy, sensitivity and specificity of the PET were 96.6 (56/58), 96.1 (49/51) and 100% (7/7), respectively. The PPV and NPV of the PET were 100 (49/49) and 77.8% (7/9), respectively. The accuracy and sensitivity of the PET were higher than those of the CT (85.1 and 88.1%), with the differences being statistically significant (p-value 0.001 and 0.003, respectively).
CONCLUSION
It is concluded that a FDG-PET scan is a more accurate and sensitive diagnostic tool than a CT scan for the detection of a recurrence or metastasis in a colorectal malignancy. In addition, a FDG-PET may alter the management of patients with recurrent colorectal cancer. Therefore, it is recommended that a PET should be considered when a tumor recurrence is suspected during conventional follow up.
  • 4,119 View
  • 28 Download
Close layer
Correlation of GLUT-1 Expression and F-18-FDG Uptake on Positron Emission Tomography in Breast Carcinoma
Gi Jeong Cheon, June Key Chung, Bo Kwang Kim, Yong Jin Lee, Dong Young Noh, Ja June Jang, Jeong Seok Yeo, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
J Korean Cancer Assoc. 2000;32(6):1067-1074.
AbstractAbstract PDF
PURPOSE
Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) has been proven to be useful in the detection of breast cancer. However, the degree of FDG uptake was variable. In this study, we evaluated the relationship between glucose transporter-1 (GLUT-1) expression with the FDG uptake in patients with breast cancer.
MATERIALS AND METHODS
15 patients with proven breast cancer underwent F-18-FDG PET. After surgical resection, anti-GLUT-1 immunohistochemical staining was performed in tumor tissues to measure the GLUT-1 expression. We evaluated the correlation between semi-quantitative FDG uptake by standardized uptake value (SUV) and GLUT-1 expression.
RESULTS
In total 15 patients, there was no significant correlation between SUV and GLUT-1 expression. We separated the patients into two groups according to the tumor size. In the group of large tumor (short diameter > or =2 cm), there was no significant correlation. However, in the group of small tumor (short diameter <2 cm), there was a significant correlation between the FDG uptake and GLUT-1 expression (rho=0.812, p=0.047).
CONCLUSION
GLUT-1 expression can influence the FDG uptake in the small breast cancers. For large breast cancers, other factors as well as GLUT-1 expression may influence the FDG uptake.
  • 2,717 View
  • 18 Download
Close layer
Role of PET Scan in Staging Work - up and Reevaluation after Therapy in Lymphoma
Young Jin Yuh, Chul Won Jung, Seock Ah Im, Dae Seog Heo, Yung Jue Bang, Seonyang Park, June Key Chung, Myung Chul Lee, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 1999;31(5):1011-1017.
AbstractAbstract PDF
PURPOSE
The authors evaluated the usefulness of the positron emission tomography (PET) with fluorine-18-tluorodeoxyglucose (8F-FDG) in initial staging, reevaluation after radical therapy and diagnosis of recurrence for non-Hodgkin's lymphoma, compaired to conventional imaging studies.
MATERIALS AND METHODS
FDG-PET (ECAT Exact 47, Siemens) and conventional chest X-ray and computerized tomography (CT) were studied in patients with non-Hodgkins lymphoma.
RESULTS
There were 17 patients (13 male, 4 female). Age was ranged from 18 to 62 years (median 49). By histological subgroup, diffuse large cell were 8 cases, peripheral T cell were 2 cases, diffuse mixed was 1 case, follicular mixed was 1 case, Burkitt's lymphoma was 1 case, Hodgkin's disease were 3 cases. The aims for PET were the initial staging work-up in 7 cases, the reevaluation of residual disease after radical therapy in 7 cases, the diagnosis of recurrence after complete remission in 3 cases. Between PET image and the conventional image, there were 3 cases with discrepancy, 1 case for initial staging work-up and 2 cases for the reevaluation of residual disease after radical therapy. Among the 3 cases with discrepancy, the 2 cases for the reevaluation of residual disease after radical therapy revealed that PET image reflects the involvement of lymphoma more accurately than the conventional image.
CONCLUSION
The visual analysis of FDG-PET would be helpful in determining the residual disease of lymphoma after radical therapy.
  • 2,614 View
  • 12 Download
Close layer
Receptors for murine monoclonal antibodies on the normal blood cells
Joon Ki Jung, Myung Chul Lee, Chang Soon Koh
J Korean Cancer Assoc. 1993;25(2):252-260.
AbstractAbstract PDF
No abstract available.
  • 1,997 View
  • 13 Download
Close layer
Comparison of biochemical assay and immunohistochemical assay of estrogen receptor in breast carcinomas
Dong Young Noh, Se Hwan Han, Kuk Jin Choe, Jin Pok Kim, Myung Chul Lee, Seong Hae Park
J Korean Cancer Assoc. 1991;23(4):749-754.
AbstractAbstract PDF
No abstract available.
  • 2,525 View
  • 13 Download
Close layer
Quantative measurement of tumor-associated antigen by autoradiography
June Key Chung, Dong Soo Lee, Myung Chul Lee, Chang Soon Koh, James C Reynolds
J Korean Cancer Assoc. 1991;23(4):740-748.
AbstractAbstract PDF
No abstract available.
  • 2,013 View
  • 13 Download
Close layer
Phase 1 Trial of Recombinant Interferon Gamma ( LBD - 001 ) in Cancer Patients
Noe Kyeong Kim, Yung Jue Bang, Dae Seog Heo, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Keun Chil Park, Dong Bok Shin, Myung Chul Lee, Byoung Kook Kim, Sang Goo Shin, Seong Hoe Park, Han Ik Cho
J Korean Cancer Assoc. 1990;22(1):86-96.
AbstractAbstract PDF
A phase I study of recombinant gamma-interferon (LBD-001) was conducted in 23 patients with advanced malignancy. The schedule was the intramuscular administration of recombinant interferon-gamma 6 consecutive days a week for 2 weeks followed by 2 weeks of rest and was repeated every 28 days. Patients were assigned to six dose levels. The maximum tolerated dose was 10.0x10(6) units/m/day and the major toxicities were flulike symptoms. After intramuscular injection, the pharmacological data fit the single compartmental modeL More than 2/3 of the dose administered was absorbed. The absorbance T 1/2 was longer with values of 247.6 minutes but interferon-gamma was cleared with a short half life of 49.9 minutes from the circulation. Antitumor effects occurred in patients with chronic myelogenous leukemia and malignant melanoma.
  • 2,679 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP